Upperton Pharma Solutions announces £5m investment into sterile drug manufacturing
Betsy Goodfellow | January 16, 2024 | News story | Manufacturing and Production | Pharmacy, Upperton Pharma Solutions, investment, sterile drug manufacturing
UK-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has announced a £5m investment to expand into a small-scale sterile fill-finish manufacturing facility.
In 2023, a new 50,000sqft GMP facility was built at Trent Gateway, Nottingham, UK; this site will now be expanded to include sterile capabilities with a “purpose-built facility designed specifically in line with the revised EU GMP Annex-1 regulations,” according to the company’s press release.
The additional 7,000sqft sterile manufacturing facility has been required due to some significant growth in demand for the formulation development and manufacturing of both sterile and terminally sterilised products.
Nikki Whitfield, chief executive officer of Upperton Pharma Solutions, commented: “This investment addresses a real shortage within our industry of providers of small batches of sterile drug products to support early clinical trials. Given our existing formulation development and analytical capabilities, it represents a natural progression for Upperton and an exciting milestone in our growth plans. […] Our leadership team fully understands the challenges of getting our clients from pre-clinical to early phase clinical studies quickly, whilst maintaining quality and regulatory compliance. The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we will enter this new market with confidence.”
The building of the facility is due to begin in February 2024, with commissioning and validation expected to be completed early in the fourth quarter of the year.
Betsy Goodfellow
Related Content
Sanofi adds €1bn funding for biomanufacturing projects in France
Sanofi has announced that it has made a new investment of at least €1bn for …
Abenza announces investment in bioconjugation and ADC capabilities
Abenza has announced a major investment in bioconjugation and antibody drug conjugate (ADC) capabilities in …
DelSiTech announces closing of €10m financing round for silica-based drug delivery platform
DelSiTech has announced the successful completion of a €10m financing round, marking the largest single …
